Connect with us

Hi, what are you looking for?

Jewish Business News

Business

Israeli Company Ready to Mass Produce Ebola Vaccine

Newark Offers Free Immunizations For Children Ahead Of The School Year

Israeli drug companies, such as Teva, are pretty good at producing imitation drugs quickly. Teva was truly disruptive to big pharma companies, since they often feared blockbuster drugs going off patent as Teva was ready and waiting with a quality generic imitation. It’s not so surprising that what is bad for big pharma is good for the patient and the consumer, and now an Israeli biotech company named Protalix is ready to replenish supplies of the experimental Ebola vaccine, ZMapp.

The disease has already claimed the lives of 3, 944, predominantly in Africa, but in the U.S., there has been one casualty and another one infected. The World Health Organization hoped to have a vaccine by November, but even if  ZMapp  can be available by the target date, supplies will be insufficient to meet requirements. However, the Times of Israel reports that Protalix can step in and produce as much ZMapp as is needed. In an interview with Channel 2, executive vice president of research and development at Protalix, Yossie Shaaltiel, said, “Today, our production capacity exceeds our needs, and we would certainly be happy to have our company produce the Ebola drug for them. We know how to do it effectively, in large quantities and in a relatively short period of time.”

I have a feeling BDS is going to be strangely silent about this outrage.

Newsletter



Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

Entertainment

The Movie The Professional is what made Natalie Portman a Lolita.

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.

Advertisement